Faculty
Oncology Division
Alphabetical list (active faculty):   
Keith E. Stockerl-Goldstein

Keith E. Stockerl-Goldstein, MD

Professor

Department of Medicine

Oncology Division

Bone Marrow Transplantation & Leukemia

Clinical Interests

  • Multiple myeloma / amyloidosis
  • Leukemia
  • Hodgkin's disease
  • Non-Hodgkin's lymphoma
  • Myelodysplastic syndrome
  • Stem cell transplantation

Contact

  • 314-454-8304 (office)
  • 314-454-7551 (fax)
  • Division of Oncology
    Mail Stop 8007-0029-11
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • 11th Floor Mid-Campus Center (office)

Peer-reviewed Articles

  • Addition of Elotuzumab to Lenalidomide and Dexamethasone for Patients With Newly Diagnosed, Transplantation Ineligible Multiple Myeloma (ELOQUENT-1): An Open-Label, Multicentre, Randomised, Phase 3 Trial
    Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksac M, Legiec W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Spicka I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K
    ELOQUENT-1 investigators (Contributors include: Stockerl-Goldstein K)
    Lancet Haematol 2022 May 9:S2352-3026(22)00103-X; [ahead of print]
  • What Do the Elevated Protein Levels Mean in My Patients With Myeloma, Amyloidosis, and Related Disorders?
    Goldsmith SR, Stockerl-Goldstein K
    Am J Med 2022 Apr;135 Suppl 1:S24-S29
  • COVID-19 and Light Chain Amyloidosis, Adding Insult to Injury
    Crees ZD, Stockerl-Goldstein K
    Am J Med 2022 Apr;135 Suppl 1:S49-S52
  • Patients Recently Treated for B-Lymphoid Malignancies Show Increased Risk of Severe COVID-19
    Rubinstein SM, Bhutani D, Lynch RC, Hsu CY, Shyr Y, Advani S, Mesa RA, Mishra S, Mundt DP, Shah DP, Sica RA, Stockerl-Goldstein KE, Stratton C, Weiss M, Beeghly-Fadiel A, Accordino M, Assouline SE, Awosika J, Bakouny Z, Bashir B, Berg S, Bilen MA, Castellano CA, Cogan JC, Kc D, Friese CR, Gupta S, Hausrath D, Hwang C, Johnson NA, Joshi M, Kasi A, Klein EJ, Koshkin VS, Kuderer NM, Kwon DH, Labaki C, Latif T, Lau E, Li X, Lyman GH, McKay RR, Nagaraj G, Nizam A, Nonato TK, Olszewski AJ, Polimera HV, Portuguese AJ, Puc MM, Razavi P, Rosovski R, Schmidt A, Shah SA, Shastri A, Su C, Torka P, Wise-Draper TM, Zubiri L, Warner JL, Thompson MA
    COVID-19 and Cancer Consortium
    Blood Cancer Discov 2022 May 5;3(3):181-193
  • An Overview of Treatment Options for Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment
    Dimopoulos MA, Mikhael J, Terpos E, Leleu X, Moreau P, Bladé J, Kim JS, Stockerl-Goldstein K, Richardson PG
    Ther Adv Hematol 2022 Apr 2;13:20406207221088458
  • Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer
    Fu J, Reid SA, French B, Hennessy C, Hwang C, Gatson NT, Duma N, Mishra S, Nguyen R, Hawley JE, Singh SRK, Chism DD, Venepalli NK, Warner JL, Choueiri TK, Schmidt AL, Fecher LA, Girard JE, Bilen MA, Ravindranathan D, Goyal S, Wise-Draper TM, Park C, Painter CA, McGlown SM, de Lima Lopes G Jr, Serrano OK, Shah DP
    COVID-19 and Cancer Consortium (CCC19) (Contributors include: Stockerl-Goldstein KE)
    JAMA Netw Open 2022 Mar 1;5(3):e224304
  • Machine Learning-Based Scoring Models to Predict Hematopoietic Stem Cell Mobilization in Allogeneic Donors
    Xiang J, Shi M, Fiala MA, Gao F, Rettig MP, Uy GL, Schroeder MA, Weilbaecher KN, Stockerl-Goldstein KE, Mollah S, DiPersio JF
    Blood Adv 2022 Apr 12;6(7):1991-2000
  • Systemic IL-15 Promotes Allogeneic Cell Rejection in Patients Treated With Natural Killer Cell Adoptive Therapy
    Berrien-Elliott MM, Becker-Hapak M, Cashen AF, Jacobs M, Wong P, Foster M, McClain E, Desai S, Pence P, Cooley S, Brunstein C, Gao F, Abboud CN, Uy GL, Westervelt P, Jacoby MA, Pusic I, Stockerl-Goldstein KE, Schroeder MA, DiPersio JF, Soon-Shiong P, Miller JS, Fehniger TA
    Blood 2022 Feb 24;139(8):1177-1183
  • Hematopoietic Cell Transplantation Donor-Derived Memory-Like NK Cells Functionally Persist After Transfer Into Patients With Leukemia
    Berrien-Elliott MM, Foltz JA, Russler-Germain DA, Neal CC, Tran J, Gang M, Wong P, Fisk B, Cubitt CC, Marin ND, Zhou AY, Jacobs MT, Foster M, Schappe T, McClain E, Kersting-Schadek S, Desai S, Pence P, Becker-Hapak M, Eisele J, Mosior M, Marsala L, Griffith OL, Griffith M, Khan SM, Spencer DH, DiPersio JF, Romee R, Uy GL, Abboud CN, Ghobadi A, Westervelt P, Stockerl-Goldstein K, Schroeder MA, Wan F, Lie WR, Soon-Shiong P, Petti AA, Cashen AF, Fehniger TA
    Sci Transl Med 2022 Feb 23;14(633):eabm1375
  • COVID-19 in Patients With Hematologic Malignancies: Outcomes and Options for Treatments
    Martínez JC, Sica RA, Stockerl-Goldstein K, Rubinstein SM
    Acta Haematol 2022 Feb 8; [Epub ahead of print]
  • NCCN Guidelines(R) Insights: Multiple Myeloma, Version 3.2022
    Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, Costello C, Devarakonda S, Elsedawy N, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Liedtke M, Martin T, Omel J, Sborov D, Shain K, Stockerl-Goldstein K, Weber D, Berardi RA, Kumar R, Kumar SK
    J Natl Compr Canc Netw 2022 Jan;20(1):8-19
  • Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States
    Hawley JE, Sun T, Chism DD, Duma N, Fu JC, Gatson NTN, Mishra S, Nguyen RH, Reid SA, Serrano OK, Singh SRK, Venepalli NK, Bakouny Z, Bashir B, Bilen MA, Caimi PF, Choueiri TK, Dawsey SJ, Fecher LA, Flora DB, Friese CR, Glover MJ, Gonzalez CJ, Goyal S, Halfdanarson TR, Hershman DL, Khan H, Labaki C, Lewis MA, McKay RR, Messing I, Pennell NA, Puc M, Ravindranathan D, Rhodes TD, Rivera AV, Roller J, Schwartz GK, Shah SA, Shaya JA, Streckfuss M, Thompson MA, Wulff-Burchfield EM, Xie Z, Yu PP, Warner JL, Shah DP, French B, Hwang C
    COVID-19 and Cancer Consortium (CCC19) (Contributors include: Stockerl-Goldstein KE)
    JAMA Netw Open 2022 Jan 4;5(1):e2142046
  • A Single Center Retrospective Study of Daratumumab, Pomalidomide, and Dexamethasone as 2nd-Line Therapy in Multiple Myeloma
    Liu L, Fiala M, Gao F, King J, Goldsmith S, Wildes TM, Stockerl-Goldstein K, Vij R, Schroeder MA
    Leuk Lymphoma 2021 Dec;62(12):3043-3046
  • How to Screen for Monoclonal Gammopathy in Patients With a Suspected Amyloidosis
    Rubinstein SM, Stockerl-Goldstein K
    JACC CardioOncol 2021 Oct 19;3(4):590-593
  • Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
    Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, Flora DB, Griffiths EA, Gulati AP, Hwang C, Koshkin VS, Papadopoulos EB, Robilotti EV, Su CT, Wulff-Burchfield EM, Xie Z, Yu PP, Mishra S, Senefeld JW, Shah DP, Warner JL
    COVID-19 and Cancer Consortium (Contributors include: Stockerl-Goldstein KE)
    JAMA Oncol 2021 Jun 17; [Epub ahead of print]
  • Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
    Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schonland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL
    ANDROMEDA Trial Investigators (Contributors include: Stockerl-Goldstein K)
    N Engl J Med 2021 Jul 1;385(1):46-58
  • Association of Clinical Factors and Recent Anticancer Therapy With COVID-19 Severity Among Patients With Cancer: A Report From the COVID-19 and Cancer Consortium
    Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY, Shyr Y, Li X, Choueiri TK, Painter CA, Peters S, Rini BI, Thompson MA, Mishra S, Rivera DR, Acoba JD, Abidi MZ, Bakouny Z, Bashir B, Bekaii-Saab T, Berg S, Bernicker EH, Bilen MA, Bindal P, Bishnoi R, Bouganim N, Bowles DW, Cabal A, Caimi PF, Chism DD, Crowell J, Curran C, Desai A, Dixon B, Doroshow DB, Durbin EB, Elkrief A, Farmakiotis D, Fazio A, Fecher LA, Flora DB, Friese CR, Fu J, Gadgeel SM, Galsky MD, Gill DM, Glover MJ, Goyal S, Grover P, Gulati S, Gupta S, Halabi S, Halfdanarson TR, Halmos B, Hausrath DJ, Hawley JE, Hsu E, Huynh-Le M, Hwang C, Jani C, Jayaraj A, Johnson DB, Kasi A, Khan H, Koshkin VS, Kuderer NM, Kwon DH, Lammers PE, Li A, Loaiza-Bonilla A, Low CA, Lustberg MB, Lyman GH, McKay RR, McNair C, Menon H, Mesa RA, Mico V, Mundt D, Nagaraj G, Nakasone ES, Nakayama J, Nizam A, Nock NL, Park C, Patel JM, Patel KG, Peddi P, Pennell NA, Piper-Vallillo AJ, Puc M, Ravindranathan D, Reeves ME, Reuben DY, Rosenstein L, Rosovsky RP, Rubinstein SM, Salazar M, Schmidt AL, Schwartz GK, Shah MR, Shah SA, Shah C, Shaya JA, Singh SRK, Smits M, Stockerl-Goldstein KE, Stover DG, Streckfuss M, Subbiah S, Tachiki L, Tadesse E, Thakkar A, Tucker MD, Verma AK, Vinh DC, Weiss M, Wu JT, Wulff-Burchfield E, Xie Z, Yu PP, Zhang T, Zhou AY, Zhu H, Zubiri L, Shah DP, Warner JL, Lopes G
    Ann Oncol 2021 Jun;32(6):787-800
  • Autologous Stem Cell Transplant for Patients With Multiple Myeloma Between Ages 75 and 78
    Fiala MA, King J, Feinberg D, Goldsmith SR, Schroeder MA, Ghobadi A, Stockerl-Goldstein KE, Vij R, Wildes TM
    Bone Marrow Transplant 2021 Aug;56(8):2016-2018
  • Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia
    Barnell EK, Newcomer KF, Skidmore ZL, Krysiak K, Anderson SR, Wartman LD, Oh ST, Welch JS, Stockerl-Goldstein KE, Vij R, Cashen AF, Pusic I, Westervelt P, Abboud CN, Ghobadi A, Uy GL, Schroeder MA, DiPersio JF, Politi MC, Spencer DH, Duncavage EJ, Ley TJ, Griffith M, Jacoby MA, Griffith OL
    JCO Precis Oncol 2021 Jan 14;5
  • A Phase I Trial Evaluating the Effects of Plerixafor, G-CSF, and Azacitidine for the Treatment of Myelodysplastic Syndromes
    Huselton E, Rettig MP, Fletcher T, Ritchey J, Gehrs L, McFarland K, Christ S, Eades WC, Trinkaus K, Romee R, Kulkarni S, Ghobadi A, Abboud C, Cashen AF, Stockerl-Goldstein K, Uy GL, Vij R, Westervelt P, DiPersio JF, Schroeder MA
    Leuk Lymphoma 2021 Jun;62(6):1441-1449
  • A Multi-Modal Diagnostic Model Improves Detection of Cardiac Amyloidosis Among Patients With Diagnostic Confirmation by Cardiac Biopsy
    Zhang KW, Zhang R, Deych E, Stockerl-Goldstein KE, Gorcsan J 3rd, Lenihan DJ
    Am Heart J 2021 Feb;232:137-145
  • Cardio-Oncology Care in the Era of the Coronavirus Disease 2019 (COVID-19) Pandemic: An International Cardio-Oncology Society (ICOS) Statement
    Lenihan D, Carver J, Porter C, Liu JE, Dent S, Thavendiranathan P, Mitchell JD, Nohria A, Fradley MG, Pusic I, Stockerl-Goldstein K, Blaes A, Lyon AR, Ganatra S, Lopez-Fernandez T, O'Quinn R, Minotti G, Szmit S, Cardinale D, Alvarez-Cardona J, Curigliano G, Neilan TG, Herrmann J
    CA Cancer J Clin 2020 Nov;70(6):480-504
  • Cardio-Oncology Education and Training: JACC Council Perspectives
    Alvarez-Cardona JA, Ray J, Carver J, Zaha V, Cheng R, Yang E, Mitchell JD, Stockerl-Goldstein K, Kondapalli L, Dent S, Arnold A, Brown SA, Leja M, Barac A, Lenihan DJ, Herrmann J
    Cardio-Oncology Leadership Council
    J Am Coll Cardiol 2020 Nov 10;76(19):2267-2281
  • Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
    Kumar SK, Callander NS, Adekola K, Anderson L, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Kang Y, Hultcrantz M, Larson S, Liedtke M, Martin T, Omel J, Shain K, Sborov D, Stockerl-Goldstein K, Weber D, Keller J, Kumar R
    J Natl Compr Canc Netw 2020 Dec 2;18(12):1685-1717
  • Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations With Response After Adoptive Immunotherapy for Leukemia
    Berrien-Elliott MM, Cashen AF, Cubitt CC, Neal CC, Wong P, Wagner JA, Foster M, Schappe T, Desai S, McClain E, Becker-Hapak M, Foltz JA, Cooper ML, Jaeger N, Srivatsan SN, Gao F, Romee R, Abboud CN, Uy GL, Westervelt P, Jacoby MA, Pusic I, Stockerl-Goldstein KE, Schroeder MA, DiPersio J, Fehniger TA
    Cancer Discov 2020 Dec;10(12):1854-1871
  • The Effect of Donor Type on Outcomes in Adults With Acute Myeloid Leukemia After Reduced-Intensity Hematopoietic Peripheral Blood Cell Transplant - A Retrospective Study
    Rashid N, Slade M, Abboud R, Gao F, DiPersio JF, Westervelt P, Uy G, Stockerl-Goldstein K, Romee R, Schroeder MA
    Transpl Int 2020 Sep;33(9):1089-1098
  • Clinical Impact of COVID-19 on Patients With Cancer (CCC19): A Cohort Study
    Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G Jr, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL
    COVID-19 and Cancer Consortium
    Lancet 2020 Jun 20;395(10241):1907-1918
  • Hematopoietic Cell Transplantation Utilization and Outcomes for Primary Plasma Cell Leukemia in the Current Era
    Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A
    Leukemia 2020 Dec;34(12):3338-3347
  • DCEP and Bendamustine/Prednisone as Salvage Therapy for Quad- and Penta-Refractory Multiple Myeloma
    Goldsmith SR, Fiala MA, Wang B, Schroeder MA, Wildes TM, Ghobadi A, Stockerl-Goldstein K, Vij R
    Ann Hematol 2020 May;99(5):1041-1048
  • Pomalidomide Plus Low-Dose Dexamethasone in Relapsed Refractory Multiple Myeloma After Lenalidomide Treatment Failure
    Siegel DS, Schiller GJ, Song KW, Agajanian R, Stockerl-Goldstein K, Kaya H, Sebag M, Samaras C, Malek E, Talamo G, Seet CS, Mouro J, Pierceall WE, Zafar F, Chung W, Srinivasan S, Agarwal A, Bahlis NJ
    Br J Haematol 2020 Feb;188(4):501-510
  • Selinexor Combined With Cladribine, Cytarabine, and Filgrastim in Relapsed or Refractory Acute Myeloid Leukemia
    Abboud R, Chendamarai E, Rettig MP, Trinkaus KM, Riedell PA, Abboud CN, Ghobadi A, Pusic I, Stockerl-Goldstein K, Schroeder MA, Vij R, Westervelt P, DiPersio JF, Uy GL
    Haematologica 2020 Aug;105(8):e404-e407
  • Maintenance Therapy Following Salvage Autologous Stem Cell Transplant in Patients With Multiple Myeloma
    Fiala MA, Vosuri V, Goldsmith S, Schroeder MA, Ghobadi A, Wildes TM, Stockerl-Goldstein KE, Vij R
    Bone Marrow Transplant 2020 Jun;55(6):1188-1190
  • GENESIS: Phase III Trial Evaluating BL-8040 + G-CSF to Mobilize Hematopoietic Cells for Autologous Transplant in Myeloma
    Crees ZD, Stockerl-Goldstein KE, Vainstein A, Chen H, DiPersio JF
    Future Oncol 2019 Nov;15(31):3555-3563
  • A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
    Schroeder MA, Fiala MA, Huselton E, Cardone MH, Jaeger S, Jean SR, Shea K, Ghobadi A, Wildes TM, Stockerl-Goldstein KE, Vij R
    Clin Cancer Res 2019 Jul 1;25(13):3776-3783
  • Outcomes of Haploidentical Vs Matched Sibling Transplantation for Acute Myeloid Leukemia in First Complete Remission
    Rashidi A, Hamadani M, Zhang MJ, Wang HL, Abdel-Azim H, Aljurf M, Assal A, Bajel A, Bashey A, Battiwalla M, Beitinjaneh AM, Bejanyan N, Bhatt VR, Bolanos-Meade J, Byrne M, Cahn JY, Cairo M, Ciurea S, Copelan E, Cutler C, Daly A, Diaz MA, Farhadfar N, Gale RP, Ganguly S, Grunwald MR, Hahn T, Hashmi S, Hildebrandt GC, Holland HK, Hossain N, Kanakry CG, Kharfan-Dabaja MA, Khera N, Koc Y, Lazarus HM, Lee JW, Maertens J, Martino R, McGuirk J, Munker R, Murthy HS, Nakamura R, Nathan S, Nishihori T, Palmisiano N, Patel S, Pidala J, Olin R, Olsson RF, Oran B, Ringden O, Rizzieri D, Rowe J, Savoie ML, Schultz KR, Seo S, Shaffer BC, Singh A, Solh M, Stockerl-Goldstein K, Verdonck LF, Wagner J, Waller EK, De Lima M, Sandmaier BM, Litzow M, Weisdorf D, Romee R, Saber W
    Blood Adv 2019 Jun 25;3(12):1826-1836
  • Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis
    Zhang KW, Stockerl-Goldstein KE, Lenihan DJ
    JACC Basic Transl Sci 2019 Jun 24;4(3):438-448
  • A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
    Ghobadi A, Fiala MA, Rettig MP, Schroeder MA, Uy GL, Stockerl-Goldstein KE, Westervelt P, Vij R, DiPersio JF
    Clin Lymphoma Myeloma Leuk 2019 Oct;19(10):e588-e593
  • Next Generation Sequencing-Based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study
    Goldsmith SR, Fiala MA, Dukeman J, Ghobadi A, Stockerl-Goldstein KE, Schroeder MA, Tomasson M, Wildes TM, Vij R
    Clin Lymphoma Myeloma Leuk 2019 May;19(5):285-289
  • Geriatric Assessment in Older Adults With Multiple Myeloma
    Wildes TM, Tuchman SA, Klepin HD, Mikhael J, Trinkaus K, Stockerl-Goldstein KE, Vij R, Colditz G
    J Am Geriatr Soc 2019 May;67(5):987-991
  • Results of an Early Access Treatment Protocol of Daratumumab in United States Patients With Relapsed or Refractory Multiple Myeloma
    Chari A, Lonial S, Mark TM, Krishnan AY, Stockerl-Goldstein KE, Usmani SZ, Londhe A, Etheredge D, Fleming S, Liu B, Ukropec J, Lin TS, Jagannath S, Nooka AK
    Cancer 2018 Nov 15;124(22):4342-4349
  • Multiple Myeloma Patients Ineligible for Randomized Controlled Trials Have Poorer Outcomes Irrespective of Treatment
    Malecek MK, Fiala M, Schroeder M, Dukeman J, Ghobadi A, Stockerl-Goldstein K, Wildes T, Vij R
    Clin Lymphoma Myeloma Leuk 2018 Sep;18(9):e363-e364
  • Secondary Acute Lymphoblastic Leukemia, a Retrospective Analysis From Washington University and Meta-Analysis of Published Data
    Ferraro F, Gao F, Stockerl-Goldstein K, Westervelt P, DiPersio JF, Ghobadi A
    Leuk Res 2018 Sep;72:86-91
  • Elotuzumab Monotherapy in Patients With Smouldering Multiple Myeloma: A Phase 2 Study
    Jagannath S, Laubach J, Wong E, Stockerl-Goldstein K, Rosenbaum C, Dhodapkar M, Jou YM, Lynch M, Robbins M, Shelat S, Anderson KC, Richardson PG
    Br J Haematol 2018 Aug;182(4):495-503
  • Impact of Dose-Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation
    Shultes KC, Arp C, Stockerl-Goldstein K, Trinkaus K, DeFrates S
    Biol Blood Marrow Transplant 2018 Apr;24(4):687-693
  • Ibrutinib Alone or With Dexamethasone for Relapsed or Relapsed and Refractory Multiple Myeloma: Phase 2 Trial Results
    Richardson PG, Bensinger WI, Huff CA, Costello CL, Lendvai N, Berdeja JG, Anderson LD Jr., Siegel DS, Lebovic D, Jagannath S, Laubach JP, Stockerl-Goldstein KE, Kwei L, Clow F, Elias L, Salman Z, Graef T, Bilotti E, Vij R
    Br J Haematol 2018 Mar;180(6):821-830
  • Long-Term Outcomes Among 2-Year Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Diffuse Large B-Cell Lymphoma
    Myers RM, Hill BT, Shaw BE, Kim S, Millard HR, Battiwalla M, Majhail NS, Buchbinder D, Lazarus HM, Savani BN, Flowers MED, D'Souza A, Ehrhardt MJ, Langston A, Yared JA, Hayashi RJ, Daly A, Olsson RF, Inamoto Y, Malone AK, DeFilipp Z, Margossian SP, Warwick AB, Jaglowski S, Beitinjaneh A, Fung H, Kasow KA, Marks DI, Reynolds J, Stockerl-Goldstein K, Wirk B, Wood WA, Hamadani M, Satwani P
    Cancer 2018 Feb 15;124(4):816-825
  • Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) Versus Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma and Non-Hodgkin Lymphoma
    Bhamidipati PK, Fiala MA, Grossman BJ, DiPersio JF, Stockerl-Goldstein K, Gao F, Uy GL, Westervelt P, Schroeder MA, Cashen AF, Abboud CN, Vij R
    Biol Blood Marrow Transplant 2017 Dec;23(12):2065-2069
  • Patterns of Infectious Complications in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients Treated With 10-Day Decitabine Regimen
    Ali AM, Weisel D, Gao F, Uy GL, Cashen AF, Jacoby MA, Wartman LD, Ghobadi A, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Schroeder MA, Westervelt P, DiPersio JF, Welch JS
    Cancer Med 2017 Dec;6(12):2814-2821
  • Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection
    Cashen AF, Rettig M, Gao F, Smith A, Abboud C, Stockerl-Goldstein K, Vij R, Uy G, Westervelt P, DiPersio J
    Biol Blood Marrow Transplant 2017 Aug;23(8):1282-1289
  • Fresh or Cryopreserved CD34+-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function After Allogeneic Hematopoietic Cell Transplantation
    Ghobadi A, Fiala MA, Ramsingh G, Gao F, Abboud CN, Stockerl-Goldstein K, Uy GL, Grossman BJ, Westervelt P, DiPersio JF
    Biol Blood Marrow Transplant 2017 Jul;23(7):1072-1077
  • Allogeneic Transplantation for Advanced Acute Myeloid Leukemia: The Value of Complete Remission
    Weisdorf DJ, Millard HR, Horowitz MM, Hyare PS, Champlin R, Ho V, Mielcarek M, Rezvani A, Stockerl-Goldstein K, Khoury HJ, De Lima M, Saber W, Sandmaier B, Zhang MJ, Eapen M
    Cancer 2017 Jun 1;123(11):2025-2034
  • Mobilization of Allogeneic Peripheral Blood Stem Cell Donors With Intravenous Plerixafor Mobilizes a Unique Graft
    Schroeder MA, Rettig MP, Lopez S, Christ S, Fiala M, Eades W, Mir FA, Shao J, McFarland K, Trinkaus K, Shannon W, Deych E, Yu J, Vij R, Stockerl-Goldstein K, Cashen AF, Uy GL, Abboud CN, Westervelt P, DiPersio JF
    Blood 2017 May 11;129(19):2680-2692
  • A Phase 1/2 Study of Chemosensitization With Plerixafor Plus G-CSF in Relapsed or Refractory Acute Myeloid Leukemia
    Uy GL, Rettig MP, Stone RM, Konopleva MY, Andreeff M, McFarland K, Shannon W, Fletcher TR, Reineck T, Eades W, Stockerl-Goldstein K, Abboud CN, Jacoby MA, Westervelt P, DiPersio JF
    Blood Cancer J 2017 Mar 10;7(3):e542
  • The Impact of Diabetes Mellitus and Other Comorbidities on Hematopoietic Stem Cell Collection and Hematologic Recovery Post-Transplantation
    Fiala MA, Slade M, Wang S, Park S, DiPersio J, Stockerl-Goldstein K
    Leuk Lymphoma 2017 Jan;58(1):241-243
  • Phase II Study of Propylene Glycol-Free Melphalan Combined With Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
    Cashen AF, Fletcher T, Ceriotti C, Gao F, Ghobadi A, Vij R, Stockerl-Goldstein K, DiPersio J, Abboud C
    Biol Blood Marrow Transplant 2016 Dec;22(12):2155-2158
  • TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
    Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ
    N Engl J Med 2016 Nov 24;375(21):2023-2036
  • A Study of High-Dose Lenalidomide Induction and Low-Dose Lenalidomide Maintenance Therapy for Patients With Hypomethylating Agent Refractory Myelodysplastic Syndrome
    Cherian MA, Tibes R, Gao F, Fletcher T, Fiala M, Uy GL, Westervelt P, Jacoby MA, Cashen AF, Stockerl-Goldstein K, DiPersio JF, Vij R
    Leuk Lymphoma 2016 Nov;57(11):2535-2540
  • Phase I Study of Azacitidine Following Donor Lymphocyte Infusion for Relapsed Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplantation
    Ghobadi A, Choi J, Fiala MA, Fletcher T, Liu J, Eissenberg LG, Abboud C, Cashen A, Vij R, Schroeder MA, Pusic I, Stockerl-Goldstein K, Jacoby M, Uy G, DiPersio J, Westervelt P
    Leuk Res 2016 Oct;49:1-6
  • Effect of Linezolid on Hematologic Recovery in Newly Diagnosed Acute Myeloid Leukemia Patients Following Induction Chemotherapy
    Nedved AN, DeFrates SR, Hladnik LM, Stockerl-Goldstein KE
    Pharmacotherapy 2016 Oct;36(10):1087-1094
  • Remobilization of Hematopoietic Stem Cells in Healthy Donors for Allogeneic Transplantation
    Fiala MA, Park S, Slade M, DiPersio JF, Stockerl-Goldstein KE
    Transfusion 2016 Sep;56(9):2331-5
  • Chemotherapy Versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Stem Cell Transplant
    Motabi IH, Ghobadi A, Liu J, Schroeder M, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, DiPersio JF
    Biol Blood Marrow Transplant 2016 Jul;22(7):1324-9
  • A Phase I Study of Thymoglobulin for Relapsed or Refractory Multiple Myeloma
    Keller J, Fiala MA, Dipersio J, Stockerl-Goldstein K, Vij R, Heldermon CD
    Leuk Lymphoma 2016 Feb;57(2):453-455
  • A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia
    Wartman LD, Fiala MA, Fletcher T, Hawkins ER, Cashen A, DiPersio JF, Jacoby MA, Stockerl-Goldstein KE, Pusic I, Uy GL, Westervelt P, Vij R
    Leuk Lymphoma 2016 Mar;57(3):728-730
  • Bendamustine, Lenalidomide, and Dexamethasone (BRD) Is Highly Effective With Durable Responses in Relapsed Multiple Myeloma
    Kumar SK, Krishnan A, LaPlant B, Laumann K, Roy V, Zimmerman T, Gertz MA, Buadi FK, Stockerl-Goldstein K, Birgin A, Fiala M, Duarte L, Maharaj M, Levy J, Vij R
    Am J Hematol 2015 Dec;90(12):1106-10
  • A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
    Hari P, Aljitawi OS, Arce-Lara C, Nath R, Callander N, Bhat G, Allen LF, Stockerl-Goldstein K
    Biol Blood Marrow Transplant 2015 Dec;21(12):2100-2105
  • Maintenance Therapy With Decitabine After Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome
    Pusic I, Choi J, Fiala MA, Gao F, Holt M, Cashen AF, Vij R, Abboud CN, Stockerl-Goldstein KE, Jacoby MA, Uy GL, Westervelt P, DiPersio JF
    Biol Blood Marrow Transplant 2015 Oct;21(10):1761-9
  • Hematologic Recovery After Pretransplant Chemotherapy Does Not Influence Survival After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients
    Vu K, Manjappa S, DiPersio JF, Gao F, Westervelt P, Vij R, Stockerl-Goldstein KE, Uy GL, Abboud CN, Schroeder MA, Fehniger TA, Cashen AF, Romee R
    Biol Blood Marrow Transplant 2015 Aug;21(8):1425-30
  • High-Dose Therapy and Autologous Stem Cell Transplant in Older Adults With Multiple Myeloma
    Wildes TM, Finney JD, Fiala M, Gao F, Vij R, Stockerl-Goldstein K, Carson KR, Mikhael J, Colditz G
    Bone Marrow Transplant 2015 Aug;50(8):1075-82
  • Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor
    Fadini GP, Fiala M, Cappellari R, Danna M, Park S, Poncina N, Menegazzo L, Albiero M, DiPersio J, Stockerl-Goldstein K, Avogaro A
    Diabetes 2015 Aug;64(8):2969-77
  • Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma
    Fiala MA, Finney JD, Stockerl-Goldstein KE, Tomasson MH, DiPersio JF, Vij R, Wildes TM
    Biol Blood Marrow Transplant 2015 Jul;21(7):1153-4
  • Carfilzomib: A Second-Generation Proteasome Inhibitor for the Treatment of Multiple Myeloma
    McBride A, Klaus JO, Stockerl-Goldstein K
    Am J Health Syst Pharm 2015 Mar 1;72(5):353-360
  • Risk of Marrow Neoplasms After Adjuvant Breast Cancer Therapy: The National Comprehensive Cancer Network Experience
    Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE
    J Clin Oncol 2015 Feb 1;33(4):340-8
  • Retrospective Comparison of Allogeneic Vs Autologous Transplantation for Diffuse Large B-Cell Lymphoma With Early Relapse or Primary Induction Failure
    Ghobadi A, Nolley E, Liu J, McBride A, Stockerl-Goldstein K, Cashen A
    Bone Marrow Transplant 2015 Jan;50(1):134-136
  • Socioeconomic Status Is Independently Associated With Overall Survival in Patients With Multiple Myeloma
    Fiala MA, Finney JD, Liu J, Stockerl-Goldstein KE, Tomasson MH, Vij R, Wildes TM
    Leuk Lymphoma 2015 Sep;56(9):2643-9
  • A Phase II Study of V-BEAM as Conditioning Regimen Before Second Auto-SCT for Multiple Myeloma
    Wang TF, Fiala MA, Cashen AF, Uy GL, Abboud CN, Fletcher T, Wu N, Westervelt P, DiPersio JF, Stockerl-Goldstein KE, Vij R
    Bone Marrow Transplant 2014 Nov;49(11):1366-70
  • Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Elderly Patients With Newly Diagnosed Multiple Myeloma
    Dytfeld D, Jasielec J, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R, Jakubowiak AJ
    Haematologica 2014 Sep;99(9):e162-4
  • Haploidentical Transplantation Using G-CSF-Mobilized T-Cell Replete PBSCs and Post-Transplantation CY After Non-Myeloablative Conditioning Is Safe and Is Associated With Favorable Outcomes
    Bhamidipati PK, DiPersio JF, Stockerl-Goldstein K, Rashidi A, Gao F, Uy GL, Westervelt P, Vij R, Schroeder MA, Abboud CN, Keller JW, Fehniger TA, Romee R
    Bone Marrow Transplant 2014 Aug;49(8):1124-6
  • A Phase I Dose Escalation Study of Oral Bexarotene in Combination With Intravenous Decitabine in Patients With AML
    Welch JS, Niu H, Uy GL, Westervelt P, Abboud CN, Vij R, Stockerl-Goldstein KE, Jacoby M, Pusic I, Schroeder MA, DiPersio JF, Cashen AF
    Am J Hematol 2014 Aug;89(8):E103-8
  • Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older With Acute Myeloid Leukemia
    Jacoby MA, Martin MG, Uy GL, Westervelt P, DiPersio JF, Cashen A, Stockerl-Goldstein K, Vij R, Luo J, Reineck T, Bernabe N, Abboud CN
    Am J Hematol 2014 May;89(5):487-92
  • Phase I Study of Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor (CLAG Regimen) and Midostaurin and All-Trans Retinoic Acid in Relapsed/Refractory AML
    Ramsingh G, Westervelt P, McBride A, Stockerl-Goldstein K, Vij R, Fiala M, Uy G, Cashen A, DiPersio JF, Abboud CN
    Int J Hematol 2014 Mar;99(3):272-8
  • The Characteristics and Outcomes of Patients With Multiple Myeloma Dual Refractory or Intolerant to Bortezomib and Lenalidomide in the Era of Carfilzomib and Pomalidomide
    Wang TF, Ahluwalia R, Fiala MA, Trinkaus KM, Cox DP, Jaenicke M, Moliske CC, Carson KR, Wildes TM, Tomasson MH, Stockerl-Goldstein KE, Vij R
    Leuk Lymphoma 2014 Feb;55(2):337-41
  • Vorinostat Plus Tacrolimus and Mycophenolate to Prevent Graft-Versus-Host Disease After Related-Donor Reduced-Intensity Conditioning Allogeneic Haemopoietic Stem-Cell Transplantation: A Phase 1/2 Trial
    Choi SW, Braun T, Chang L, Ferrara JL, Pawarode A, Magenau JM, Hou G, Beumer JH, Levine JE, Goldstein S, Couriel DR, Stockerl-Goldstein K, Krijanovski OI, Kitko C, Yanik GA, Lehmann MH, Tawara I, Sun Y, Paczesny S, Mapara MY, Dinarello CA, DiPersio JF, Reddy P
    Lancet Oncol 2014 Jan;15(1):87-95
  • Protective Effect of Cytomegalovirus Reactivation on Relapse After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Conditioning Regimen
    Manjappa S, Bhamidipati PK, Stockerl-Goldstein KE, DiPersio JF, Uy GL, Westervelt P, Liu J, Schroeder MA, Vij R, Abboud CN, Fehniger TA, Cashen AF, Pusic I, Jacoby M, Meera SJ, Romee R
    Biol Blood Marrow Transplant 2014 Jan;20(1):46-52
  • A Phase 1 Study of Concomitant High-Dose Lenalidomide and 5-Azacitidine Induction in the Treatment of AML
    Ramsingh G, Westervelt P, Cashen AF, Uy GL, Stockerl-Goldstein K, Abboud CN, Bernabe N, Monahan R, DiPersio JF, Vij R
    Leukemia 2013 Mar;27(3):725-8
  • Influence of Body Mass Index on Survival in Veterans With Multiple Myeloma
    Beason TS, Chang SH, Sanfilippo KM, Luo S, Colditz GA, Vij R, Tomasson MH, DiPersio JF, Stockerl-Goldstein K, Ganti A, Wildes T, Carson KR
    Oncologist 2013;18(10):1074-9
  • A Phase 1/2 Study of Carfilzomib in Combination With Lenalidomide and Low-Dose Dexamethasone as a Frontline Treatment for Multiple Myeloma
    Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Nordgren B, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R
    Blood 2012 Aug 30;120(9):1801-9
  • Oral Valganciclovir Versus Ganciclovir as Delayed Pre-Emptive Therapy for Patients After Allogeneic Hematopoietic Stem Cell Transplant: A Pilot Trial (04-0274) and Review of the Literature
    Chawla JS, Ghobadi A, Mosley J 3rd, Verkruyse L, Trinkaus K, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Uy GL, Westervelt P, DiPersio JF, Vij R
    Transpl Infect Dis 2012 Jun;14(3):259-67
  • A Phase 1/2 Study of Chemosensitization With the CXCR4 Antagonist Plerixafor in Relapsed or Refractory Acute Myeloid Leukemia
    Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Vij R, Westervelt P, DiPersio JF
    Blood 2012 Apr 26;119(17):3917-24
  • Tandem Chemo-Mobilization Followed by High-Dose Melphalan and Carmustine With Single Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
    Chen AI, Negrin RS, McMillan A, Shizuru JA, Johnston LJ, Lowsky R, Miklos DB, Arai S, Weng WK, Laport GG, Stockerl-Goldstein K
    Bone Marrow Transplant 2012 Apr;47(4):516-21
  • Classifying Cytogenetics in Patients With Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study
    Armand P, Kim HT, Zhang MJ, Perez WS, Dal Cin PS, Klumpp TR, Waller EK, Litzow MR, Liesveld JL, Lazarus HM, Artz AS, Gupta V, Savani BN, McCarthy PL, Cahn JY, Schouten HC, Finke J, Ball ED, Aljurf MD, Cutler CS, Rowe JM, Antin JH, Isola LM, Di Bartolomeo P, Camitta BM, Miller AM, Cairo MS, Stockerl-Goldstein K, Sierra J, Savoie ML, Halter J, Stiff PJ, Nabhan C, Jakubowski AA, Bunjes DW, Petersdorf EW, Devine SM, Maziarz RT, Bornhauser M, Lewis VA, Marks DI, Bredeson CN, Soiffer RJ, Weisdorf DJ
    Biol Blood Marrow Transplant 2012 Feb;18(2):280-8
  • Long-Term Outcome of Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells
    Muller AM, Kohrt HE, Cha S, Laport G, Klein J, Guardino AE, Johnston LJ, Stockerl-Goldstein KE, Hanania E, Juttner C, Blume KG, Negrin RS, Weissman IL, Shizuru JA
    Biol Blood Marrow Transplant 2012 Jan;18(1):125-33
  • Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated With Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation
    Smeltzer JP, Cashen AF, Zhang Q, Homb A, Dehdashti F, Abboud CN, DiPersio JF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, Bartlett NL, Fehniger TA
    Biol Blood Marrow Transplant 2011 Nov;17(11):1646-52
  • Combination Decitabine, Arsenic Trioxide, and Ascorbic Acid for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Phase I Study
    Welch JS, Klco JM, Gao F, Procknow E, Uy GL, Stockerl-Goldstein KE, Abboud CN, Westervelt P, DiPersio JF, Hassan A, Cashen AF, Vij R
    Am J Hematol 2011 Sep;86(9):796-800
  • A Phase 2 Study of High-Dose Lenalidomide as Initial Therapy for Older Patients With Acute Myeloid Leukemia
    Fehniger TA, Uy GL, Trinkaus K, Nelson AD, Demland J, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Westervelt P, DiPersio JF, Vij R
    Blood 2011 Feb 10;117(6):1828-33
  • Salvage Therapy for Acute Myeloid Leukemia With Fludarabine, Cytarabine, and Idarubicin With or Without Gemtuzumab Ozogamicin and With Concurrent or Sequential G-CSF
    Martin MG, Augustin KM, Uy GL, Welch JS, Hladnik L, Goyal S, Tiwari D, Monahan RS, Reichley RM, Cashen AF, Stockerl-Goldstein K, Westervelt P, Abboud CN, DiPersio JF, Vij R
    Am J Hematol 2009 Nov;84(11):733-7
  • A Phase II Study of 5-Day Intravenous Azacitidine in Patients With Myelodysplastic Syndromes
    Martin MG, Walgren RA, Procknow E, Uy GL, Stockerl-Goldstein K, Cashen AF, Westervelt P, Abboud CN, Kreisel F, Augustin K, DiPersio JF, Vij R
    Am J Hematol 2009 Sep;84(9):560-4
  • A Meta-Analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sezary Syndrome
    Wu PA, Kim YH, Lavori PW, Hoppe RT, Stockerl-Goldstein KE
    Biol Blood Marrow Transplant 2009 Aug;15(8):982-90
  • Allo-SCT Conditioning for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Clofarabine, Cytarabine and ATG
    Martin MG, Uy GL, Procknow E, Stockerl-Goldstein K, Cashen A, Westervelt P, Abboud CN, Augustin K, Luo J, DiPersio JF, Vij R
    Bone Marrow Transplant 2009 Jul;44(1):13-7
  • Bortezomib Administered Pre-Auto-SCT and as Maintenance Therapy Post Transplant for Multiple Myeloma: A Single Institution Phase II Study
    Uy GL, Goyal SD, Fisher NM, Oza AY, Tomasson MH, Stockerl-Goldstein K, DiPersio JF, Vij R
    Bone Marrow Transplant 2009 May;43(10):793-800
  • High-Dose Chemotherapy Followed by Stem Cell Rescue for High-Risk Germ Cell Tumors: The Stanford Experience
    Agarwal R, Dvorak CC, Stockerl-Goldstein KE, Johnston L, Srinivas S
    Bone Marrow Transplant 2009 Apr;43(7):547-52
  • Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation
    Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS, Smith AL, DiPersio JF
    Biol Blood Marrow Transplant 2008 Sep;14(9):1045-56
  • High-Dose Carmustine, Etoposide, and Cyclophosphamide Followed by Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma
    Law LY, Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R, Shizuru JA, Blume KG, Negrin RS, Stockerl-Goldstein KE
    Biol Blood Marrow Transplant 2006 Jul;12(7):703-11
  • Protective Conditioning for Acute Graft-Versus-Host Disease
    Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Hoppe RT, Bloch DA, Blume KG, Negrin RS, Strober S
    N Engl J Med 2005 Sep 29;353(13):1321-31
  • Engraftment and Survival Following Reduced-Intensity Allogeneic Peripheral Blood Hematopoietic Cell Transplantation Is Affected by CD8+ T-Cell Dose
    Cao TM, Shizuru JA, Wong RM, Sheehan K, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Stuart MJ, Grumet FC, Negrin RS, Lowsky R
    Blood 2005 Mar 15;105(6):2300-6
  • CD34, CD4, and CD8 Cell Doses Do Not Influence Engraftment, Graft-Versus-Host Disease, or Survival Following Myeloablative Human Leukocyte Antigen-Identical Peripheral Blood Allografting for Hematologic Malignancies
    Cao TM, Wong RM, Sheehan K, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Negrin RS, Lowsky R
    Exp Hematol 2005 Mar;33(3):279-85
  • Rapamycin (Sirolimus) for Treatment of Chronic Graft-Versus-Host Disease
    Johnston LJ, Brown J, Shizuru JA, Stockerl-Goldstein KE, Stuart MJ, Blume KG, Negrin RS, Chao NJ
    Biol Blood Marrow Transplant 2005 Jan;11(1):47-55
  • A Randomized Trial of Amifostine and Carmustine-Containing Chemotherapy to Assess Lung-Protective Effects
    Jones RB, Stockerl-Goldstein KE, Klein J, Murphy J, Blume KG, Dansey R, Martinez C, Matthes S, Nieto Y
    Biol Blood Marrow Transplant 2004 Apr;10(4):276-82
  • Rituximab as Adjuvant to High-Dose Therapy and Autologous Hematopoietic Cell Transplantation for Aggressive Non-Hodgkin Lymphoma
    Horwitz SM, Negrin RS, Blume KG, Breslin S, Stuart MJ, Stockerl-Goldstein KE, Johnston LJ, Wong RM, Shizuru JA, Horning SJ
    Blood 2004 Feb 1;103(3):777-83
  • Allografting With Nonmyeloablative Conditioning Following Cytoreductive Autografts for the Treatment of Patients With Multiple Myeloma
    Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W, Storer B, Hegenbart U, Somlo G, Chauncey T, Bruno B, Appelbaum FR, Blume KG, Forman SJ, McSweeney P, Storb R
    Blood 2003 Nov 1;102(9):3447-54
  • Rapid Establishment of Dendritic Cell Chimerism in Allogeneic Hematopoietic Cell Transplant Recipients
    Auffermann-Gretzinger S, Lossos IS, Vayntrub TA, Leong W, Grumet FC, Blume KG, Stockerl-Goldstein KE, Levy R, Shizuru JA
    Blood 2002 Feb 15;99(4):1442-8
  • Rapid Engraftment After Allogeneic Transplantation of Density-Enriched Peripheral Blood CD34+ Cells in Patients With Advanced Hematologic Malignancies
    Cao TM, Kusnierz-Glaz C, Valone F, Stockerl-Goldstein KE, Hu WW, Johnston L, Blume KG, Strober S, Negrin RS
    Cancer 2001 Jun 15;91(12):2205-13
  • Efficacy and Toxicity of a CCNU-Containing High-Dose Chemotherapy Regimen Followed by Autologous Hematopoietic Cell Transplantation in Relapsed or Refractory Hodgkin's Disease
    Stuart MJ, Chao NS, Horning SJ, Wong RM, Negrin RS, Johnston LJ, Shizuru JA, Long GD, Blume KG, Stockerl-Goldstein KE
    Biol Blood Marrow Transplant 2001;7(10):552-60
  • High-Dose Therapy and Autologous Hematopoietic-Cell Transplantation for Follicular Lymphoma Beyond First Remission: The Stanford University Experience
    Cao TM, Horning S, Negrin RS, Hu WW, Johnston LJ, Taylor TL, Shizuru JA, Hoppe RT, Brown BW, Blume KG, Stockerl-Goldstein KE
    Biol Blood Marrow Transplant 2001;7(5):294-301
  • Effect of Oral Glutamine Supplementation During Bone Marrow Transplantation
    Coghlin Dickson TM, Wong RM, offrin RS, Shizuru JA, Johnston LJ, Hu WW, Blume KG, Stockerl-Goldstein KE
    JPEN J Parenter Enteral Nutr 2000 Mar-Apr;24(2):61-6
  • Idiotype Vaccination Using Dendritic Cells After Autologous Peripheral Blood Progenitor Cell Transplantation for Multiple Myeloma
    Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, Benike CJ, Reichardt V, van Beckhoven A, Rajapaksa R, Engleman EG, Blume KG, Levy R
    Biol Blood Marrow Transplant 2000;6(6):621-7
  • Toxicity of High-Dose Sequential Chemotherapy and Purged Autologous Hematopoietic Cell Transplantation Precludes Its Use in Refractory/Recurrent Non-Hodgkin's Lymphoma
    Johnston LJ, Stockerl-Goldstein KE, Hu WW, Negrin RS, Hoppe RT, Blume KG, Horning SJ
    Biol Blood Marrow Transplant 2000;6(5A):555-62
  • Favorable Treatment Outcome in Non-Hodgkin's Lymphoma Patients With "Poor" Mobilization of Peripheral Blood Progenitor Cells
    Stockerl-Goldstein KE, Reddy SA, Horning SF, Blume KG, Chao NF, Hu WW, Johnston LF, Long GD, Strober S, Wong RM, Feiner RH, Kobler S, Negrin RS
    Biol Blood Marrow Transplant 2000;6(5):506-12
  • High-Dose Chemotherapy and Hematopoietic Stem Cell Rescue for Breast Cancer: Experience in California
    Damon LE, Hu WW, Stockerl-Goldstein KE, Blume KG, Wolf JL, Gold E, Cecchi GR, Irwin D, Glaspy J, Territo I, Miller W, Mason JR, Linker CA
    Biol Blood Marrow Transplant 2000;6(5):496-505
  • Pulmonary Toxicity Syndrome in Breast Cancer Patients Undergoing BCNU-Containing High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation
    Cao TM, Negrin RS, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Taylor TL, Rizk NW, Wong RM, Blume KG, Hu WW
    Biol Blood Marrow Transplant 2000;6(4):387-94
  • High-Dose Therapy With Hematopoietic Cell Transplantation for Patients With Central Nervous System Involvement by Non-Hodgkin's Lymphoma
    Alvarnas JC, Negrin RS, Horning SJ, Hu WW, Long GD, Schriber JR, Stockerl-Goldstein K, Tierney K, Wong R, Blume KG, Chao NJ
    Biol Blood Marrow Transplant 2000;6(3A):352-8
  • Transplantation of Highly Purified CD34+Thy-1+ Hematopoietic Stem Cells in Patients With Metastatic Breast Cancer
    Negrin RS, Atkinson K, Leemhuis T, Hanania E, Juttner C, Tierney K, Hu WW, Johnston LJ, Shizurn JA, Stockerl-Goldstein KE, Blume KG, Weissman IL, Bower S, Baynes R, Dansey R, Karanes C, Peters W, Klein J
    Biol Blood Marrow Transplant 2000;6(3):262-71
  • Equivalence of 2 Effective Graft-Versus-Host Disease Prophylaxis Regimens: Results of a Prospective Double-Blind Randomized Trial
    Chao NJ, Snyder DS, Jain M, Wong RM, Niland JC, Negrin RS, Long GD, Hu WW, Stockerl-Goldstein KE, Johnston LJ, Amylon MD, Tierney DK, O'Donnell MR, Nademanee AP, Parker P, Stein A, Molina A, Fung H, Kashyap A, Kohler S, Spielberger R, Krishnan A, Rodriguez R, Forman SJ, Bluzme KG
    Biol Blood Marrow Transplant 2000;6(3):254-61
  • Four-Cycle High-Dose Therapy With Hematopoietic Support for Metastatic Breast Cancer: No Improvement in Outcomes Compared With Single-Course High-Dose Therapy
    Hu WW, Negrin RS, Stockerl-Goldstein K, Johnston LJ, Shizuru JA, Wong RM, Chao NJ, Long GD, Feiner RH, Blume KG
    Biol Blood Marrow Transplant 2000;6(1):58-69
  • A Feasibility Study of Multiple Cycle Therapy With Melphalan, Thiotepa, and Paclitaxel Followed by Mitoxantrone, Thiotepa, and Paclitaxel With Autologous Hematopoietic Cell Support for Metastatic Breast Cancer
    Hu WW, Long GD, Stockerl-Goldstein KE, Johnston LJ, Chao NJ, Negrin RS, Blume KG
    Clin Cancer Res 1999 Nov;5(11):3411-8
  • Idiotype Vaccination Using Dendritic Cells After Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma--A Feasibility Study
    Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, Blume KG, Levy R
    Blood 1999 Apr 1;93(7):2411-9
  • Impact of Admission Body Weight and Chemotherapy Dose Adjustment on the Outcome of Autologous Bone Marrow Transplantation
    Dickson TM, Kusnierz-Glaz CR, Blume KG, Negrin RS, Hu WW, Shizuru JA, Johnston LL, Wong RM, Stockerl-Goldstein KE
    Biol Blood Marrow Transplant 1999;5(5):299-305
  • Fractionated Total-Body Irradiation, Etoposide, and Cyclophosphamide Followed by Allogeneic Bone Marrow Transplantation for Patients With High-Risk or Advanced-Stage Hematological Malignancies
    Long GD, Amylon MD, Stockerl-Goldstein KE, Negrin RS, Chao NJ, Hu WW, Nademanee AP, Snyder DS, Hoppe RT, Vora N, Wong R, Niland J, Reichardt VL, Forman SJ, Blume KG
    Biol Blood Marrow Transplant 1997 Dec;3(6):324-30
  • Rationale for Adjuvant Idiotypic Vaccination After High-Dose Therapy for Multiple Myeloma
    Reichardt VL, Okada CY, Stockerl-Goldstein KE, Bogen B, Levy R
    Biol Blood Marrow Transplant 1997 Aug;3(3):157-63
  • Influence of Preparatory Regimen and Source of Hematopoietic Cells on Outcome of Autotransplantation for Non-Hodgkin's Lymphoma
    Stockerl-Goldstein KE, Horning SJ, Negrin RS, Chao NJ, Hu WW, Long GD, Hoppe RT, Amylon MD, Brown BW Jr, Wong RM, Blume KG
    Biol Blood Marrow Transplant 1996 May;2(2):76-85

Invited Publications

  • Chronic Leukemias
    Shea LK, Stockerl-Goldstein K
    In: The Washington Manual of Oncology, 4th Edition (Morgensztern D, Ghobadi A, Govindan R, Editors), Wolters Kluwer, Philadelphia, 2022
  • NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020
    Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Cornell RF, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Holmberg L, Htut M, Huff CA, Kang Y, Landgren O, Malek E, Martin T, Omel J, Raje N, Sborov D, Singhal S, Stockerl-Goldstein KE, Tan C, Weber D, Johnson-Chilla A, Keller J, Kumar R
    J Natl Compr Canc Netw 2019 Oct 1;17(10):1154-1165
  • NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018
    Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kang Y, Kassim A, Liedtke M, Malek E, Martin T, Neppalli VT, Omel J, Raje N, Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Kumar R, Shead DA
    J Natl Compr Canc Netw 2018 Jan;16(1):11-20
  • Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
    Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, Martin T, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R
    J Natl Compr Canc Netw 2017 Feb;15(2):230-269
  • Chronic Leukemias
    Bhamidipati PK, Stockerl-Goldstein KE
    In: Govindan R, Morgensztern D (Eds.), DeVita, Hellman and Rosenberg’s Cancer: Principles and Practice of Oncology Review (Ed 4) 2016, Philadelphia PA, Wolters Kluwer
  • NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016
    Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R
    J Natl Compr Canc Netw 2016 Apr;14(4):389-400
  • Commentary
    Stockerl-Goldstein K
    Clin Chem 2012 Apr;58(4):675
  • Chronic Leukemias
    Mosley JC, Stockerl-Goldstein K
    In: Govindan R (Ed.), DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology Review (Ed 3) 2012, Baltimore, MD, Lippincott Williams and Wilkins
  • Multiple Myeloma
    Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber EA Jr, Gasparetto C, Huff CA, Kassim A, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F
    J Natl Compr Canc Netw 2011 Oct;9(10):1146-83
  • Chronic Leukemias
    Mosley JC, Stockerl-Goldstein K
    In: Govindan R (Ed.), DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology Review (Ed 2) 2009, Baltimore, MD, Lippincott Williams and Wilkins
  • NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma
    Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA, Jagasia M, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Tricot G, Vose JM, Weber D, Yahalom J, Yunus F
    J Natl Compr Canc Netw 2009 Oct;7(9):908-42
  • Multiple Myeloma. Clinical Practice Guidelines in Oncology
    Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Comenzo RL, De Castro CM, Djulbegovic B, Farag S, Huff CA, Meredith R, Schriber J, Shrieve D, Singhal S, Smith MR, Stockerl-Goldstein K, Vose JM, Weber D, Yahalom J, Yunus F
    J Natl Compr Canc Netw 2007 Feb;5(2):118-47
  • Amyloidosis
    Stockerl-Goldstein K
    In: Scharschmidt BF (Ed.): PocketMedicine/Internal Medicine 2nd Edition, New York, PocketMedicine.com, Inc., 2002
  • Allogeneic Transplantation for Adult Patients With Acute Myeloid Leukemia
    Stockerl-Goldstein K, Blume KG
    In: Blume KG, Forman SJ, Appelbaum FR (Eds.): Thomas' Hematopoietic Cell Transplantation (Ed 3), Malden, MA, Blackwell Science, Inc., 2003
  • Amyloidosis
    Stockerl-Goldstein K
    In: Scharschmidt BF (Ed.): PocketMedicine/Internal Medicine, Philadelphia, PocketMedicine.com, Inc., 2002
  • A Decade of Progress in Allogeneic Hematopoietic Cell Transplantation: 1990-2000
    Stockerl-Goldstein KE, Blume KG
    Adv Cancer Res 2001;81:1-59
  • Allogeneic Transplantation for Adult Patients With Acute Myeloid Leukemia
    Stockerl-Goldstein K, Blume KG
    In: Thomas ED, Blume KG, Forman SJ (Eds.): Hematopoietic Cell Transplantation (Ed 2), Malden, MA, Blackwell Science, Inc., 1998
  • NCCN Practice Guidelines for Multiple Myeloma
    Anderson KC, Bensinger W, Bernstein S, Biermann S, Meredith R, Michaeli J, Noga SJ, Stockerl-Goldstein K, Traynor A, Weber D, Yahalom J
    Oncology 1998;12:317-351